Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.
D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics / Q000378:metabolism; D015703:Antigens, CD / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects; D001500:BCG Vaccine / Q000235:genetics*; D019496:Cancer Vaccines; D002277:Carcinoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D003001:Cloning, Molecular; D018274:Electroporation; D005260:Female; D015870:Gene Expression / Q000235:genetics; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D018664:Interleukin-12 / Q000235:genetics; D007378:Interleukins / Q000378:metabolism; D051379:Mice; D008809:Mice, Inbred C3H; D009163:Mycobacterium bovis / Q000235:genetics; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D019444:Vaccines, DNA / Q000627:therapeutic use
D000942:Antigens, Bacterial; D015703:Antigens, CD; D001500:BCG Vaccine; D019496:Cancer Vaccines; D007378:Interleukins; D019253:Proto-Oncogene Proteins c-bcl-2; D019444:Vaccines, DNA; D018664:Interleukin-12